Keyphrases
Adverse Events
8%
Backscatter
15%
Backscatter Analysis
12%
Becker muscular Dystrophy
9%
Chronic Inflammatory Demyelinating Polyneuropathy
7%
Clinical Trials
8%
Corticosteroids
12%
Delandistrogene Moxeparvovec
16%
Disease Progression
9%
Duchenne muscular Dystrophy
100%
Dystrophin
16%
Electrical Impedance Myography
19%
Electrodiagnosis
7%
Gene Therapy
17%
Givinostat
9%
Grayscale Level
10%
Intraclass Correlation Coefficient
10%
Muscle Thickness
9%
Muscle Ultrasound
8%
Muscular Dystrophy
9%
Myopathy
8%
Nerve
19%
Nerve Enlargement
8%
Nerve Transfer
6%
Nerve Ultrasound
10%
Neuromuscular Disease
15%
Non-ambulatory
10%
Non-ambulatory Patients
6%
Nusinersen
10%
Onasemnogene Abeparvovec
20%
Pediatric
6%
Phase II Trial
12%
Phenotypic Spectrum
6%
Placebo
7%
Placebo-controlled
9%
Polyneuropathy
6%
PYROXD1
6%
Quantitative muscle Ultrasound
10%
Quantitative Ultrasound
22%
Randomized Double-blind
9%
Skeletal muscle
10%
SMN2
9%
SMN2 Copies
7%
Spinal muscular Atrophy
33%
Spinal muscular Atrophy Type 1
8%
Ultrasound
26%
Ultrasound Examination
12%
United States
8%
Viltolarsen
9%
Young children
14%
Medicine and Dentistry
Adverse Event
14%
Arm
10%
Bayley Scales of Infant Development
5%
Becker Muscular Dystrophy
9%
Blood Flow
6%
Chronic Inflammatory Demyelinating Polyneuropathy
6%
Clinical Trial
8%
Combination Therapy
7%
Disease Exacerbation
8%
Diseases
6%
Duchenne Muscular Dystrophy
91%
Dystrophin
15%
Echography
8%
Electrodiagnosis
11%
Exon
7%
Gene Therapy
16%
Givinostat
9%
Limb
9%
Magnetic Resonance Imaging
6%
Median Nerve
5%
Muscle Disease
10%
Myography
19%
Myopathy
11%
Nerve Transplantation
6%
Neuromuscular Disease
7%
Neuropathy
7%
Onasemnogene Abeparvovec
17%
Pediatrics
6%
Peripheral Nerve
5%
Placebo
11%
Polyneuropathy
6%
Skeletal Muscle
16%
Spinal Cord Injury
5%
Spinal Muscular Atrophy
23%
Ultrasonography of Muscle
17%
Upper Limb
11%
Viltolarsen
9%
Werdnig Hoffmann Disease
8%
